Abstract: Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
Type:
Grant
Filed:
May 13, 1999
Date of Patent:
October 17, 2006
Assignee:
Nuvelo, Inc.
Inventors:
Lewis T. Williams, Jaime Escobedo, Michael A. Innis, Pablo Dominguez Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C. Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Birgit Stache-Crain
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human secreted IGFBP-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted IGFBP-like polypeptides, compositions, and methods of use for such polypeptides including in cancer.
Type:
Grant
Filed:
August 12, 2002
Date of Patent:
September 19, 2006
Assignee:
Nuvelo, Inc.
Inventors:
Douglas A. Dedera, Victoria Yamazaki, Vinod Asundi, Chenghua Liu, Y. Tom Tang, Radoje T. Drmanac
Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.
Type:
Application
Filed:
January 17, 2006
Publication date:
July 20, 2006
Applicant:
NUVELO, Inc.
Inventors:
Bryan Boyle, Peter Emtage, Walter Funk, Y. Tang, Jingsong Zhao
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human prothrombinase-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human ovary (Hyseq clone identification number 7735656). Other aspects of the invention include vectors containing processes for producing novel human prothrombinase-like polypeptides, and antibodies specific for such polypeptides.
Type:
Grant
Filed:
March 13, 2003
Date of Patent:
June 27, 2006
Assignee:
Nuvelo, Inc.
Inventors:
Dana A. Haley, Bryan J. Boyle, Alice S. Ho, Matthew C. Arterburn, Nancy K. Mize
Abstract: Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.
Type:
Application
Filed:
January 11, 2006
Publication date:
May 18, 2006
Applicant:
NUVELO, Inc.
Inventors:
Douglas Dedera, Jian-Rui Wang, Peter Emtage
Abstract: Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.
Type:
Grant
Filed:
December 19, 2002
Date of Patent:
April 18, 2006
Assignee:
Nuvelo, Inc.
Inventors:
Douglas Dedera, Jian-Rui Wang, Peter C. R. Emtage
Abstract: The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and fetal liver as well as polypeptides encoded by these polynucleotides. The polypeptide is a human chemokine receptor that is a member of a family of G protein-coupled receptors characterized by seven transmembrane domains. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing chemokine receptor polypeptides, and antibodies specific for such polypeptides.
Abstract: The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and fetal liver as well as polypeptides encoded by these polynucleotides. The polypeptide is a human chemokine receptor that is a member of a family of G protein-coupled receptors characterized by seven transmembrane domains. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing chemokine receptor polypeptides, and antibodies specific for such polypeptides.
Abstract: Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.
Abstract: Provided by the present invention are methods for treating and diagnosing preeclampsia, as well as kits for use in diagnosing patients with a higher risk of preeclampsia.
Type:
Application
Filed:
April 7, 2004
Publication date:
November 17, 2005
Applicant:
NUVELO, Inc.
Inventors:
Ivan Labat, Y. Tang, Birgit Stache-Crain, Bryan Boyle
Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
Type:
Grant
Filed:
January 28, 1999
Date of Patent:
November 15, 2005
Assignee:
Nuvelo, Inc.
Inventors:
Lewis T. Williams, Jaime Escobedo, Michael A. Innis, Pablo Dominguez Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C. Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Birgit Stache-Crain
Abstract: Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.
Abstract: Certain cells, including types of cancer cells such as KIRHy1, are capable of expressing KIRHy1 mRNA. Targeting using KIRHy1 polypeptides, nucleic acids encoding for KIRHy1 polypeptides and anti-KIRHy1 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy1 protein. Methods of therapy and diagnosis of disorders associated with KIRHy1 protein-expressing cells, such as B cell lymphoma, are described.
Type:
Application
Filed:
December 2, 2003
Publication date:
September 22, 2005
Applicant:
NUVELO, Inc.
Inventors:
Peter Emtage, Ping Zhou, Vinod Asundi, Y. Tang, Radoje Drmanac
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel insulin growth factor-like (IGFL) polypeptides. Other aspects of the invention include vectors containing processes for producing novel IGFL polypeptides, and antibodies specific for such polypeptides.